Close Menu

mergers & acquisitions

Qiagen’s goal is to enable its customers to take an assay in a very early stage of discovery and validation and, “without transitioning platforms — to seamlessly move that into a companion diagnostic candidate if they so wish."

The $1.1 billion deal for the MDS Analytical Technologies business is under antitrust review.

Cell Biosciences will pay Alpha Innotech's shareholders $1.50 per share, giving the deal a total consideration of $17.9 million.

The Belgian life sciences company sees the acquisition as bringing together the firm's respective genomics and proteomics capabilities and their European and US presences.

BD plans to place its GeneOhm assays on HandyLab's Jaguar system.

MDS' shareholders voted in favor of the deal at a special meeting on Tuesday.

OriGene gains products for DNA and RNA purification and multiplex assays for genotyping, microRNA profiling, and transcription factor activity analysis.

BGIP sells a range of bioscience products that are "tailored" to the Indian market, said the German firm.

Silence said that it "expects the proposed transaction to be treated as a reverse takeover … [and will be] subject to due diligence and would be conditional upon shareholder approval."

While CombiMatrix did not disclose the terms within which a recently hired investment bank will serve as its "financial and strategic advisor," such moves typically are overtures to mergers, acquisitions, or asset divestitures.

Pages

President Donald Trump announced the US would be leaving the World Health Organization, NBC News reports.

A study of Great Danes homes in on a genomic region linked to fearfulness.

CDC head says a new analysis indicates earlier testing wouldn't have caught viral spread, NPR reports.

In PLOS this week: gene expression and epigenetics of Indonesian populations, hookworm parasite secretome, and more.